Literature DB >> 20596672

Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.

Lucia Cicchillitti1, Anna Della Corte, Michela Di Michele, Maria Benedetta Donati, Domenico Rotilio, Giovanni Scambia.   

Abstract

Ovarian cancer is the second most frequently diagnosed malignancy of the reproductive system and is the leading cause of gynecological cancer mortality. Although the majority of advanced ovarian carcinomas initially respond successfully to taxane-based chemotherapy, resistance to chemotherapy remains the primary factor accounting for the low 5-year survival in this patient population. Recent data obtained by our group demonstrate that the disulphide isomerase ERp57 is strongly modulated in paclitaxel resistance suggesting that it may represent a chemoresistance biomarker in ovarian cancer. In the present study, we characterise a nuclear multimeric complex where ERp57 is associated with protein species involved in cell division and gene expression, as Nucleolin, Nucleophosmin, Vimentin, Aurora kinase C and beta-actin. In particular, we show that the occurrence of the interaction of nuclear ERp57 with beta-actin is associated with paclitaxel resistance and that specific actin conformations modulate this complex. We propose the involvement of the nuclear ERp57 complex in mechanisms associated with chromosome segregation in which specific conformational states of actin play a role in the pathway involved in paclitaxel resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596672     DOI: 10.3892/ijo_00000693

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis.

Authors:  Naiara Santana-Codina; Rafael Carretero; Rebeca Sanz-Pamplona; Teresa Cabrera; Emre Guney; Baldo Oliva; Philippe Clezardin; Omar E Olarte; Pablo Loza-Alvarez; Andrés Méndez-Lucas; Jose Carlos Perales; Angels Sierra
Journal:  Mol Cell Proteomics       Date:  2013-04-26       Impact factor: 5.911

2.  Tumor necrosis factor-α treatment of HepG2 cells mobilizes a cytoplasmic pool of ERp57/1,25D₃-MARRS to the nucleus.

Authors:  Brian J Grindel; Benjamin Rohe; Susan E Safford; Joseph J Bennett; Mary C Farach-Carson
Journal:  J Cell Biochem       Date:  2011-09       Impact factor: 4.429

Review 3.  Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.

Authors:  Aubryanna Hettinghouse; Ronghan Liu; Chuan-Ju Liu
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

4.  Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.

Authors:  Stella Sun; T S Wong; X Q Zhang; Jenny K S Pu; Nikki P Lee; Philip J R Day; Gloria K B Ng; W M Lui; Gilberto K K Leung
Journal:  J Neurooncol       Date:  2011-10-07       Impact factor: 4.130

5.  Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer.

Authors:  Jason B Nikas; Kristin L M Boylan; Amy P N Skubitz; Walter C Low
Journal:  Cancer Inform       Date:  2011-10-03

6.  Actin and Keratin are Binding Partners of the 1,25D3-MARRS Receptor/PDIA3/ERp57.

Authors:  Tremaine LeBlanc; Lka Nemere
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2014-08

7.  ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer.

Authors:  Min Ho Choe; Joong Won Min; Hong Bae Jeon; Dong-Hyung Cho; Jeong Su Oh; Hyun Gyu Lee; Sang-Gu Hwang; Sungkwan An; Young-Hoon Han; Jae-Sung Kim
Journal:  Oncotarget       Date:  2015-02-20

8.  Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis.

Authors:  Miao Liu; Lingyao Du; Zhiliang He; Libo Yan; Ying Shi; Jin Shang; Hong Tang
Journal:  Biomed Res Int       Date:  2017-03-08       Impact factor: 3.411

9.  Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma.

Authors:  Jian Shen; Weizhi Wang; Jindao Wu; Bing Feng; Wen Chen; Meng Wang; Jincao Tang; Fuqiang Wang; Feng Cheng; Liyong Pu; Qiyun Tang; Xuehao Wang; Xiangcheng Li
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Whole genome expression profiling of blood cells in ovarian cancer patients -prognostic impact of the CYP1B1, MTSS1, NCALD, and NOP14.

Authors:  Helena S Isaksson; Bengt Sorbe; Torbjörn K Nilsson
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.